Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017870 | 0.91 | KCNE1 (0.47) | TACR1CCR1KCNE1KCNQ1KDM4E | |
| SCHEMBL6018064 | 0.87 | KCNE1 (0.44) | TACR1CCR1KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL6017839 | 0.85 | SCD (0.46) | CCR1KCNE1KCNQ1MAOBSMN1; SMN2 | |
| SCHEMBL6017627 | 0.85 | KCNE1 (0.54) | CCR1KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL6017708 | 0.85 | KCNE1 (0.48) | CCR1KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL6017737 | 0.84 | KCNE1 (0.44) | CCR1KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL6018572 | 0.83 | KMT2A (0.49) | CCR1KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL6018223 | 0.83 | CNR1 (0.48) | CCR1KCNE1KCNQ1 | |
| SCHEMBL6017784 | 0.82 | P2RX7 (0.45) | CCR1KCNE1KCNQ1 | |
| SCHEMBL6017779 | 0.82 | KCNE1 (0.42) | CCR1KCNE1KCNQ1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | claimed |
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | TACR1 3949/4885MLYCD 2798/4885CCR1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.